胃がん治療市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、がんタイプ別、投与経路別、薬剤クラス別、流通チャネル別、地域別セグメント、競合、2020年～2030年

胃がん治療の世界市場規模は2024年に55億1,000万米ドルで、予測期間中のCAGRは14.84%で2030年には126億4,000万米ドルに達すると予測されています。

胃がん治療の世界市場は、胃がんを治療するための新薬や治療法の開発が進むことにより、大きな成長を遂げています。さらに、痛みのない低コスト治療への需要の高まりと、がん治療に対する有利な償還シナリオが、世界各地で胃がん治療の成長を著しく高めています。さらに、胃がんのようなさまざまな種類の慢性疾患に罹患しやすい高齢化人口が世界中で増加していることから、さまざまながん治療に対する需要がさらに増加し、2030年までの市場成長が加速すると予想されます。

市場促進要因

世界的に高い疾患負担が持続

主な市場課題

低資源環境における診断の遅れ

主要市場動向

標準治療としての免疫療法

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の胃がん治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療タイプ別（免疫療法、標的療法、化学療法、放射線療法、その他）
  • がんタイプ別（胃がん／胃食道接合部がん、消化管間質腫瘍）
  • 投与経路別（経口、注射剤）
  • 薬剤クラス別（PD-1/PD-L1阻害剤、HER2拮抗薬、VEGFR2拮抗薬、その他）
  • 流通チャネル別（病院薬局、専門薬局、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 治療タイプ別
  • がんタイプ別
  • 投与経路別
  • 薬剤クラス別
  • 流通チャネル別
  • 地域別

第6章 北米の胃がん治療の市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の胃がん治療の市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の胃がん治療の市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の胃がん治療の市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの胃がん治療の市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威/サービス

第14章 SWOT分析：世界の胃がん治療市場

第15章 競合情勢

• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann La Roche AG
• Mylan N.V.
• Celltrion Healthcare Co., Ltd
• Merck KGaA
• Samsung Bioepis

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Stomach Cancer Treatment Market was valued at USD 5.51 billion in 2024 and is expected to reach USD 12.64 billion by 2030 with a CAGR of 14.84% during the forecast period. The global market for Stomach Cancer Treatment is experiencing significant growth, driven by the growing development of novel drugs and therapies for treating stomach cancer. Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenario for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe. Additionally, growing aging population across the globe which is more prone to different kinds of chronic diseases like stomach cancer is further expected to increase the demand for different cancer therapies, thereby fuelling the market growth through 2030.

Key Market Drivers

Persistent High Disease Burden Worldwide

Stomach (gastric) cancer continues to pose a serious global health threat. The World Health Organization reports approximately 1 million new cases annually, with nearly 800,000 deaths, ranking it among the top five causes of cancer-related mortality. Although incidence rates have declined in many Western countries due to improved food preservation and H. pylori management, global case numbers remain stable due to rising trends in several Asian and Latin American nations. This high disease burden fuels sustained demand for advanced treatment options-from surgical procedures to chemotherapy, targeted agents, and emerging immunotherapies-for both localized and advanced-stage diseases. Governments are responding for instance, Japan and South Korea have implemented national screening programs that detect early-stage cancers in 50%-60% of patients, vastly improving outcomes. In lower-income regions, late diagnosis (with 5-year survival below 20%) underscores a continued need for treatment expansion.

In addition, the aging global population contributes to rising incidence: the UN projects that the number of individuals over age 65 will double by 2050, and since age is a primary risk factor, this will further increase the prevalence of stomach cancer. These factors combine to drive robust investment from public health agencies, cancer centers, and pharmaceutical companies in treatment development, including supportive therapies and advanced surgical techniques.

Key Market Challenges

Late Diagnosis in Low-Resource Settings

In many regions without national screening programs, stomach cancer is still detected late, when curative options are limited. Globally, less than 10% of cases are diagnosed at Stage I outside East Asia, leading to 5-year survival rates below 20%. The lack of affordable diagnostic infrastructure-including endoscopy, imaging, and molecular profiling-limits access, even in countries with high disease burden. Additionally, stigma and low public awareness hinder early presentation. During the COVID-19 pandemic, diagnoses fell by 40% in South Asia, exacerbating the problem. Even in nations with existing screening systems, rural or lower-income populations may face barriers to care-amplifying health inequities.

Addressing this requires investment in lower-cost but high-impact diagnostic methods (e.g., breath tests, tele-endoscopy), public awareness programs, and distributed diagnostic services. Without improving early detection, treatment advances may reach only a minority of patients, limiting overall population health impact.

Key Market Trends

Immunotherapy as a Standard of Care

Immunotherapy is rapidly emerging as a transformative modality in gastric cancer treatment. While early trials showed modest results, recent Phase III studies have demonstrated median overall survival extending beyond 12 months when combining immunotherapy with chemotherapy in first-line advanced disease. Pembrolizumab and nivolumab are now commonly employed in frontline regimens in many countries.

In parallel, biomarkers like PD-L1 combining positive score (CPS) and tumor mutational burden are being integrated into routine diagnostic panels, guiding patient selection. Major healthcare systems-including the U.S. Medicare program-have approved reimbursement for PD-L1 testing in gastric cancer. Japan and South Korea have also revised clinical guidelines to recommend immunotherapy in HER2-negative, PD-L1-positive cases within the past year. With over 10 ongoing Phase III trials exploring immunotherapy in perioperative or second-line settings, its use is expected to become further standardized. As the technology matures, research is also exploring combinations with vaccines, oncolytic viruses, and adoptive cell therapies, opening new frontiers in personalized cancer care.

Key Market Players

• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann La Roche AG
• Mylan N.V.
• Celltrion Healthcare Co., Ltd
• Merck KGaA
• Samsung Bioepis

Report Scope:

In this report, the Global Stomach Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Stomach Cancer Treatment Market, By Treatment Type:

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Radiation Therapy
• Others

Stomach Cancer Treatment Market, By Cancer Type:

• Gastric Cancer/Gastroesophageal Junction Cancer
• Gastrointestinal Stromal Tumors

Stomach Cancer Treatment Market, By Route of Administration:

• Oral
• Injectables

Stomach Cancer Treatment Market, By Drug Class:

• PD-1/PD-L1 Inhibitors
• HER2 Antagonists
• VEGFR2 Antagonists
• Others

Stomach Cancer Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Specialty Pharmacies
• Others

Stomach Cancer Treatment Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Stomach Cancer Treatment Market.

Available Customizations:

Global Stomach Cancer Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Stomach Cancer Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others)
  • 5.2.2. By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors)
  • 5.2.3. By Route of Administration (Oral v/s Injectables)
  • 5.2.4. By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Treatment Type
  • 5.3.2. By Cancer Type
  • 5.3.3. By Route of Administration
  • 5.3.4. By Drug Class
  • 5.3.5. By Distribution Channel
  • 5.3.6. By Region

6. North America Stomach Cancer Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Cancer Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Drug Class
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Stomach Cancer Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Drug Class
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Stomach Cancer Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Drug Class
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Stomach Cancer Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Drug Class
      • 6.3.3.2.5. By Distribution Channel

7. Europe Stomach Cancer Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Cancer Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Drug Class
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Stomach Cancer Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Drug Class
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. Germany Stomach Cancer Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Drug Class
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Stomach Cancer Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Drug Class
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Stomach Cancer Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Drug Class
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Stomach Cancer Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Drug Class
      • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Stomach Cancer Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Cancer Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Drug Class
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Stomach Cancer Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Drug Class
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Stomach Cancer Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Drug Class
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Stomach Cancer Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Drug Class
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Stomach Cancer Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Cancer Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Drug Class
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Stomach Cancer Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Cancer Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Drug Class
      • 8.3.5.2.5. By Distribution Channel

9. South America Stomach Cancer Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Cancer Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Drug Class
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Stomach Cancer Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Drug Class
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. Argentina Stomach Cancer Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Drug Class
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Colombia Stomach Cancer Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Drug Class
      • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Stomach Cancer Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Cancer Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Drug Class
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Stomach Cancer Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Drug Class
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Saudi Arabia Stomach Cancer Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Drug Class
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. UAE Stomach Cancer Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Drug Class
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products/Services

14. SWOT Analysis: Global Stomach Cancer Treatment Market

15. Competitive Landscape

• 15.1. Pfizer, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Eli Lilly and Company
• 15.4. Bristol-Myers Squibb Company
• 15.5. Teva Pharmaceutical Industries Ltd.
• 15.6. F. Hoffmann La Roche AG
• 15.7. Mylan N.V.
• 15.8. Celltrion Healthcare Co., Ltd
• 15.9. Merck KGaA
• 15.10. Samsung Bioepis

16. Strategic Recommendations

17. About Us & Disclaimer